The European Parliament has approved a new Directive on Trade Secrets which, according to the European Public Health Alliance (EPHA) means that trade secrets will outweigh the public interest. EPHA believes there will be a negative impact on health as information on the safety of medicines will be considered commercially confidential and kept secret from patients, regulators and the public.The Trade Secrets Law would gag journalists and whistle-blowers, undermining freedom of expression and preventing vital information reaching the media and public. With regard to public health, the new rules would erect a barrier to public access to data on the safety and efficacy of medicines.
The proposals for the Trade Secrets Directive are clearly intended to increase commercial confidentiality in the interest of drug makers who seek to keep clinical trials results secret, and would weaken patient safety protection and halt further research and independent analyses.
For more information about the Directive on Trade Secrets on the epha.org website